{"denoms":[{"counts":[{"groupId":"BG000","value":"50"}],"units":"Participants"}],"groups":[{"description":"Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.","id":"BG000","title":"Bone Marrow Transplantation Using Nexell Isolex 300i"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"46"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10","value":"33"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"50"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}